A biopharmaceutical company focused on antiviral therapies, oncology, and cell therapy, with a leading portfolio in HIV treatment and prevention. Revenue is driven primarily by its HIV franchise, alongside growing contributions from oncology and liver disease products. Investors track the company for its patent cycle management, pipeline development, and capital allocation strategy, including acquisitions and share repurchases.
3 members of Congress have disclosed 4 trades in Gilead Sciences, Inc. (GILD), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2006-02-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2005-05-10 | Vern Buchanan | buy | $1K – $15K |
| 2004-08-08 | Lamar Smith | sell | $775.55 |
| 2004-05-10 | Lamar Smith | sell | $1K – $15K |